Comprehensive evaluation and treatment planning for cervical cancer, with the approach selected according to tumour stage, size, lymph node involvement, fertility considerations and overall health.
Cervical cancer develops in the cells of the cervix, the lower portion of the uterus that connects to the vagina.
Persistent infection with high-risk types of human papillomavirus (HPV) is the major cause of cervical cancer. Changes in cervical cells can develop gradually and may be detected through screening before invasive cancer develops.
When cervical cancer is diagnosed, treatment depends on the stage, tumour size, lymph node involvement, fertility considerations and the patient's overall health.
HPV vaccination and regular cervical screening can help prevent cervical cancer or detect precancerous changes before invasive disease develops.
The cervix forms the lower part of the uterus and connects the uterus with the vagina.
The cervical canal forms the passage between the uterus and vagina.
The inner portion of the cervix contains glandular cells that produce cervical mucus.
The outer portion of the cervix projects into the upper vagina and contains squamous cells.
The transformation zone is where glandular and squamous cells meet and is the area where most cervical cancers begin.
Most cervical cancers are squamous cell carcinomas arising from the squamous cells covering the outer cervix.
Adenocarcinoma develops from glandular cells of the cervix and is the second most common major type of cervical cancer.
This tumour contains features of both squamous cell carcinoma and adenocarcinoma.
Less common cervical malignancies include certain neuroendocrine and other rare tumour types that require specialised assessment.
Persistent infection with high-risk HPV types is the major cause of cervical cancer.
HPV is a very common infection. Most HPV infections clear naturally, but persistent infection with certain high-risk HPV types can cause abnormal changes in cervical cells.
Over time, some precancerous changes can progress to invasive cervical cancer if they are not detected and treated.
HPV vaccination and regular cervical screening are important tools for reducing the risk of cervical cancer.
HPV vaccination, appropriate cervical screening and follow-up of abnormal screening results can help reduce cervical cancer risk.
Early cervical cancer may cause no symptoms. Possible symptoms of invasive disease include:
Bleeding between periods, after sexual intercourse or after menopause can require evaluation.
Persistent watery, bloody or foul-smelling vaginal discharge may occur.
Pelvic pain or discomfort, particularly during sexual intercourse, can occur.
Persistent pain during sexual intercourse should be evaluated, particularly when accompanied by other symptoms.
Advanced cervical cancer can sometimes affect nearby urinary structures and cause urinary symptoms.
Swelling of the legs can occur in more advanced disease when lymphatic drainage is affected.
Cervical screening is used to detect HPV infection and abnormal cervical cells before invasive cancer develops.
Depending on age, risk factors and local screening guidelines, screening can involve HPV testing, cervical cytology or a combination of approaches.
An abnormal screening result does not automatically mean that a person has cervical cancer. Additional evaluation may be required to determine whether precancerous changes or cancer are present.
Regular screening can identify cervical changes at an earlier stage, when they can often be managed before invasive cancer develops.
Testing can identify infection with high-risk HPV types associated with cervical cancer.
Cytology examines cervical cells for abnormal changes.
A colposcopic examination allows closer inspection of abnormal areas of the cervix.
A biopsy can provide tissue for microscopic examination when abnormal areas require further evaluation.
A clinical examination can assess the cervix and surrounding structures for visible or palpable abnormalities.
Suspicious cervical areas can be examined under magnification and sampled for pathological assessment.
MRI, CT or PET-CT may be used when appropriate to evaluate tumour extent and possible lymph node or distant involvement.
Histopathological examination confirms the tumour type and provides information important for treatment planning.
Abnormal cervical cells do not always represent invasive cancer. Precancerous changes can often be treated before cancer develops.
Low-grade cervical changes may resolve naturally and are often managed with appropriate follow-up.
Moderate-grade changes may require closer monitoring or treatment depending on individual circumstances.
High-grade precancerous changes generally require appropriate treatment to reduce the risk of progression to invasive cancer.
Procedures such as LEEP or cone biopsy may be used for selected precancerous lesions.
Early-stage cervical cancer may be treated with surgery in selected patients, with the exact procedure depending on tumour characteristics and fertility considerations.
In carefully selected very early cancers, removal of a cone-shaped portion of the cervix may be considered.
Removal of the uterus and cervix may be considered for selected early-stage cervical cancers.
Radical hysterectomy is a surgical procedure used for selected early-stage cervical cancers. It involves removal of the uterus and cervix along with surrounding tissues and, when appropriate, regional lymph nodes.
The exact extent of surgery depends on the tumour's size, location, stage and relationship to nearby structures.
Minimally invasive or open approaches may be considered depending on the patient's individual circumstances and the surgical plan.
Radical surgery is considered only for selected cervical cancers where surgery provides an appropriate treatment option.
In carefully selected young patients with small early-stage cervical cancers, fertility-preserving surgery may be considered.
Removal of a cone-shaped portion of the cervix may be appropriate for selected very early cancers.
Radical trachelectomy removes the cervix and surrounding tissues while preserving the uterus in selected patients.
Fertility preservation depends on tumour size, stage, histology, lymph node status and other clinical factors.
Pregnancy after fertility-preserving treatment requires specialised obstetric care and individual assessment.
Cervical cancer can spread to regional lymph nodes, making lymph node assessment an important component of treatment planning in selected stages.
Sentinel lymph node assessment may be considered in selected early cervical cancers.
Pelvic lymph nodes may be removed or assessed depending on tumour stage and surgical planning.
Examination of lymph nodes provides important information about cancer spread and can influence additional treatment.
For many locally advanced cervical cancers, combined chemotherapy and radiation is an important treatment approach rather than surgery alone.
Radiation is delivered to the pelvis to treat the cervical tumour and areas at risk of microscopic disease.
Brachytherapy delivers radiation close to the cervical tumour and is an important component of definitive treatment in appropriate patients.
Chemotherapy may be given during radiation to enhance treatment effectiveness in appropriate locally advanced disease.
Surgery, radiation oncology and medical oncology may work together to determine the most appropriate treatment sequence.
Treatment for advanced or recurrent cervical cancer is selected based on the sites of disease, previous treatment and overall health.
Chemotherapy and other systemic treatments may be used when disease is recurrent or metastatic.
Selected patients may be considered for targeted treatments based on tumour characteristics.
Immunotherapy can be considered for selected cervical cancers depending on disease characteristics and prior treatment.
Radiation, procedures and systemic therapy may be used to control symptoms and disease when cure is not possible.
Recurrent cervical cancer can return in the pelvis or appear at distant sites. Treatment depends on where the cancer has returned, previous treatments and whether the recurrent disease can be treated locally.
Selected patients with isolated pelvic recurrence may be evaluated for additional surgery or radiation-based treatment.
More widespread recurrence may require systemic treatment such as chemotherapy, targeted therapy or immunotherapy.
Previous surgery, radiation and systemic treatment all influence the options available when cervical cancer recurs.
The stage and biological characteristics of the cancer guide the treatment pathway.
Establish the tumour type through appropriate examination and pathology.
Assess tumour size, local extension and regional or distant spread.
Consider fertility preservation when it is medically appropriate and important to the patient.
Determine whether surgery, chemoradiation, systemic therapy or a combined approach is appropriate.
Dr. Nitin Singhal is a surgical oncologist in Ahmedabad with experience in complex cancer surgery and multidisciplinary cancer care.
Cervical cancer treatment requires careful assessment of tumour stage, local extension and lymph node involvement. Surgical options are considered according to the individual disease characteristics and overall treatment plan.
Cervical cancer develops in the cervix, the lower part of the uterus. Persistent infection with high-risk HPV is the major cause of cervical cancer, and regular screening can help detect precancerous changes before invasive disease develops.
The most common cervical cancers are squamous cell carcinoma and adenocarcinoma. Diagnosis may involve cervical examination, colposcopy, biopsy and imaging to determine the extent of disease.
Treatment depends on the stage and characteristics of the cancer. Selected early-stage cancers may be treated with conization, hysterectomy or fertility-preserving surgery such as trachelectomy. Lymph node assessment may also form part of surgical treatment.
For many locally advanced cervical cancers, concurrent chemotherapy and radiation, including brachytherapy, is an important treatment approach. Recurrent or metastatic disease may require systemic treatment, targeted therapy or immunotherapy depending on the individual case.
If you have been diagnosed with cervical cancer or have an abnormal cervical screening result, specialist evaluation can help clarify the diagnosis, stage and appropriate treatment options.
Common questions about cervical cancer screening, surgery and treatment.
Get a personalised evaluation to understand your diagnosis, cancer stage, surgical options and whether fertility-preserving or other treatment approaches may be appropriate for you.
Dr. Nitin Singhal has been recognised for his contribution to cancer care and surgical oncology, reflecting his commitment to advanced surgical techniques, clinical excellence and patient-centred care.
Surgical oncology training from Tata Memorial Hospital, Mumbai.
Expertise across complex and multidisciplinary cancer surgery.
Honoured for excellence in healthcare and surgical oncology.
Focus on evidence-based and personalised cancer treatment.
Recognition that reflects a continued commitment to excellence in cancer care.
